埃索美拉唑联合莫沙必利在食管炎治疗中的应用及有效性研究  

Study on the Application and Effectiveness of Esomeprazole Combined with Mosapride in the Treatment of Esophagitis

作　　者：武益含 WU Yihan(Endoscopy Center,Chaoyang Second Hospital,Chaoyang,Liaoning 122000,China)

机构地区：[1]朝阳市第二医院内镜中心,辽宁朝阳122000

出　　处：《中国医药指南》2025年第12期85-88,共4页Guide of China Medicine

摘　　要：目的 研究埃索美拉唑联合莫沙必利应用在食管炎患者治疗中所发挥的治疗作用。方法 将2024年1月至2024年9月来朝阳市第二医院接受治疗的109例食管炎患者经过随机分组方法分为观察组(55例)和对照组(54例)。对照组采用奥美拉唑+多潘立酮+胶体果胶铋治疗,观察组则采用埃索美拉唑+莫沙必利+胶体果胶铋治疗,对两组患者的临床疗效、治疗前后食管动力指标、疼痛、生活质量及用药反应进行统计和对比。结果 (1)观察组的临床疗效高于对照组(P<0.05);(2)治疗前,两组患者的食管括约肌压力、卧位反流时间百分比、立体位反流时间百分比差异无统计学意义(P> 0.05),治疗8周后,观察组的食管括约肌压力、卧位反流时间百分比、立体位反流时间百分比比对照组改善更好(P<0.05);(3)治疗前两组患者的VAS、QOL评分差异无统计学意义(P> 0.05),治疗8周后,观察组的VAS、QOL评分比对照组改善更好(P<0.05);(4)观察组的用药不良反应发生率比对照组更低(P<0.05)。结论 将埃索美拉唑联合莫沙必利应用在食管炎患者的治疗中能提高临床疗效,改善患者的食管动力学指标,减轻疼痛并提高生活质量,且用药安全性高,对促进患者的病情恢复有重要的帮助。Objective To investigate the therapeutic effect of esomeprazole combined with mosapride in the treatment of patients with esophagitis.Methods A total of 109 patients with esophagitis who were treated at Chaoyang Second Hospital from January 2024 to September 2024 were randomly divided into an observation group(55 patients)and a control group(54 patients).The control group received omeprazole+domperidone+colloidal bismuth pectinate for treatment,while the observation group received esomeprazole+mosapride+colloidal bismuth pectinate.The clinical efficacy,esophageal motility indicators before and after treatment,pain,quality of life,and medication reactions were statistically analyzed and compared between the two groups.Results(1)The observation group demonstrated superior therapeutic effectiveness relative to the control cohort(P<0.05).(2)Initial assessments revealed comparable baseline measurements between groups regarding esophageal sphincter pressure metrics,supine reflux duration proportion,and upright reflux time percentage,with no statistically meaningful disparities(P>0.05).Following 8 weeks of therapeutic intervention,the observation group exhibited significantly greater enhancements in these physiological parameters compared to the control group(P<0.05).(3)Pretreatment evaluations showed equivalent visual analog scale(VAS)scores and quality of life(QOL)assessments across both groups(P>0.05).Subsequent analysis after the 8 weeks treatment regimen revealed statistically significant improvements in both pain perception(VAS)and life quality metrics(QOL)favoring the observation group(P<0.05).(4)Comparative safety analysis indicated that the observation group experienced fewer treatmentrelated adverse events than the control group(P<0.05).Conclusions The therapeutic use of esomeprazole in combination with mosapride demonstrates significant clinical benefits for esophagitis patients,including enhanced treatment efficacy and improved esophageal motor function parameters.This dual-drug regimen effectively alleviate

关 键 词：埃索美拉唑 莫沙必利 食管炎 食管动力 疼痛 不良反应 

分 类 号：R571[医药卫生—消化系统]